Sci Immunol 2021 Feb 26;6(56):eabb7221. Daniel Dwyer, Ph.D. Abstract Mast cells (MCs) play a pathobiologic role in type 2 (T2) allergic inflammatory diseases of the airway, including asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP). Distinct MC subsets infiltrate the airway mucosa in T2 disease, including subepithelial MCs expressing the proteases tryptase and chymase (MCTC)Continue reading “Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation”
Category Archives: Uncategorized
P2Y6 signaling in alveolar macrophages prevents leukotriene-dependent type 2 allergic lung inflammation)
The Journal of Clinical Investigation (JCI) Jun Nagai, Ph.D. Abstract Antagonists of the type 1 cysteinyl leukotriene receptor (CysLT1R) are widely used to treat asthma and allergic rhinitis, with variable response rates. Alveolar macrophages express UDP-specific P2Y6 receptors that can be blocked by off-target effects of CysLT1R antagonists. Sensitizing intranasal doses of an extract fromContinue reading “P2Y6 signaling in alveolar macrophages prevents leukotriene-dependent type 2 allergic lung inflammation)”
Cysteinyl leukotriene receptor 2 drives lung immunopathology through a platelet and high mobility box 1-dependent mechanism
Mucosal Immunol. 2019 May; 12(3): 679–690. Tao Liu, Ph.D. Abstract Cysteinyl leukotrienes (cysLTs) facilitate eosinophilic mucosal type 2 immunopathology, especially in aspirin-exacerbated respiratory disease (AERD), by incompletely understood mechanisms. We now demonstrate that platelets, activated through the type 2 cysLT receptor (CysLT2R), cause IL-33-dependent immunopathology through a rapidly inducible mechanism requiring the actions of highContinue reading “Cysteinyl leukotriene receptor 2 drives lung immunopathology through a platelet and high mobility box 1-dependent mechanism”
